H. Lundbeck A/S Presents Phase Ib Data, Starts Phase II Study
H. Lundbeck A/S announced results from a Phase Ib study for Lu AF28996 in advanced Parkinson's disease and has initiated a Phase II study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, begins Phase II trial
Lundbeck has presented Phase Ib clinical trial data for its investigational drug Lu AF28996, which is being studied for the treatment of advanced Parkinson's disease. The company has also initiated a Phase II trial for the same indication.
Lundbeck presents Phase Ib data for Lu AF28996 in Parkinson's
H Lundbeck A/S presented Phase Ib data for Lu AF28996 in advanced Parkinson's disease, showing it increases good on-time, reduces off-time and dyskinesia severity. A Phase II trial for the drug is now underway.